GSK taps Covance for clinical trials tech
As per the agreement, GSK will use Covance’s Xcellerate Monitoring, Xcellerate Insights, and Xcellerate Clinical Data Hub solutions.
The Princeton, NJ-based contact research organization (CRO) will support GSK with implementation beginning in the first half of 2018.
Dimitris Agrafiotis, PhD, chief data officer and head of Technology Products at Covance, told us the company is excited to collaborate with GSK in the software-as-a-service (SaaS) model.
“The Xcellerate Monitoring solution offers an objective, data-driven approach to clinical-trial monitoring that enables proactive identification and mitigation of risk at the study, site and subject level to safeguard patient safety, improve data quality, increase operational efficiency, and enable full transparency and oversight of study conduct and performance,” he explained.
The solution uses adaptive central-monitoring methodology to enable sponsors to guide site monitoring resources to the sites that need the most attention, Agrafiotis said.
“These capabilities are enabled by a state-of-the-art clinical data integration layer that provides timely, secure, integrated, and contextualized access to all clinical trial data through a unique user experience,” he added.
